Products
Fazpilodemab Biosimilar Bispecific Antibody (β-Klotho × FGFR1) for Research
Cat No.: GMP-Bios-INN-1200
Anti-KLB therapeutic antibody (Pre-made Fazpilodemab biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Fazpilodemab (development codes BFKB-8488A/RG7992) is a bispecific monoclonal antibody targeting KLB (b-Klotho) and FGFR1. It is developed by Genentech for non-alcoholic steatohepatitis. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1200-1mg | 1mg | |
| GMP-Bios-INN-1200-10mg | 10mg | |
| GMP-Bios-INN-1200-100mg | 100mg | |
| GMP-Bios-INN-1200-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Fazpilodemab biosimilar, Bispecific mAb, Anti-KLB;FGFR1/CD331/BFGFR Antibody: Anti-KLB/Beta-klotho/BKL/BetaKlotho therapeutic antibody |
| INN Name | Fazpilodemab |
| Target | KLB;FGFR1/CD331/BFGFR |
| Format | Bispecific mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | Genentech |
| Conditions Approved | na |
| Conditions Active | Non-alcoholic steatohepatitis |
| Conditions Discontinued | Type 2 diabetes mellitus |
| Production | na |
| Development Tech | na |
